NCT03111628View on ClinicalTrials.gov

Role of Immunoglobulin E (IgE) Bearing Cells in Chronic Idiopathic Urticaria (CIU)

PHASE4CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

October 6, 2017

Primary Completion Date

May 1, 2020

Study Completion Date

May 1, 2020

Conditions
Urticaria Chronic
Interventions
DRUG

Omalizumab

omalizumab 300 mg every 4 weeks by subcutaneous injection

Trial Locations (1)

21224

Johns Hopkins Asthma and Allergy Center, Baltimore

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

Johns Hopkins University

OTHER

NCT03111628 - Role of Immunoglobulin E (IgE) Bearing Cells in Chronic Idiopathic Urticaria (CIU) | Biotech Hunter | Biotech Hunter